lifestyle.celebhomes.net
Home
Sample Page
Author:
Oryzon Genomics, S.A.
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
May 14, 2026
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
May 13, 2026
ORYZON to Participate in Upcoming Events in May and June
April 29, 2026
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
March 25, 2026
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax
March 23, 2026
ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
March 12, 2026
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
February 10, 2026
ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan
February 2, 2026